Atezolizumab/hyaluronidase

{{Short description|Combination medication}}

{{Use American English|date=September 2024}}

{{Use dmy dates|date=September 2024}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{Infobox drug

| type = combo

| image =

| width =

| alt =

| caption =

| component1 = Atezolizumab

| class1 = Monoclonal antibody

| component2 = Hyaluronidase

| class2 = Endoglycosidase

| tradename = Tecentriq Hybreza

| Drugs.com = {{drugs.com|parent|Tecentriq-hybreza}}

| MedlinePlus =

| DailyMedID = Atezolizumab and hyaluronidase

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category =

| routes_of_administration = Subcutaneous

| ATC_prefix = None

| ATC_suffix =

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment =

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| CAS_number =

| CAS_supplemental =

| PubChem =

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG =

| ChEBI =

| ChEMBL =

| synonyms =

}}

Atezolizumab/hyaluronidase, sold under the brand name Tecentriq Hybreza, is a fixed-dose combination medication used for the treatment of non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma. It contains atezolizumab, a programmed death-ligand 1 (PD-L1) blocking monoclonal antibody; and hyaluronidase (human recombinant), an endoglycosidase. It is taken by subcutaneous injection.{{cite web | title=Tecentriq Hybreza- atezolizumab and hyaluronidase-tqjs injection | website=DailyMed | date=25 September 2024 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a617b089-ce66-464b-987b-b45d029b4d6f | access-date=5 October 2024}}

The most common adverse reactions include fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite.

Atezolizumab/hyaluronidase was approved for medical use in the United States in September 2024.{{cite web | title=FDA approves atezolizumab and hyaluronidase-tqjs | website=U.S. Food and Drug Administration | date=12 September 2024 | url=https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-and-hyaluronidase-tqjs-subcutaneous-injection | access-date=14 September 2024 | archive-date=14 September 2024 | archive-url=https://web.archive.org/web/20240914055712/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-and-hyaluronidase-tqjs-subcutaneous-injection | url-status=live }} {{PD-notice}}{{cite press release | title=FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy | website=Genentech | date=12 September 2024 | url=https://www.gene.com/media/press-releases/15035/2024-09-12/fda-approves-genentechs-tecentriq-hybrez | access-date=14 September 2024 | archive-date=13 September 2024 | archive-url=https://web.archive.org/web/20240913041829/https://www.gene.com/media/press-releases/15035/2024-09-12/fda-approves-genentechs-tecentriq-hybrez | url-status=live }}{{cite press release | title=Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza With Enhanze for Multiple Types of Cancer | publisher=Halozyme Therapeutics | via=PR Newswire | date=12 September 2024 | url=https://www.prnewswire.com/news-releases/halozyme-announces-fda-approval-of-roches-tecentriq-hybreza-with-enhanze-for-multiple-types-of-cancer-302247280.html | access-date=14 September 2024 | archive-date=13 September 2024 | archive-url=https://web.archive.org/web/20240913013612/https://www.prnewswire.com/news-releases/halozyme-announces-fda-approval-of-roches-tecentriq-hybreza-with-enhanze-for-multiple-types-of-cancer-302247280.html | url-status=live }}